←
Airfinity824 posts
Airfinity avatar

Airfinity

@Airfinity

Airfinity tracks, simulates, and predicts population level disease outcomes in real time to inform decisions that can increase the global lifespan.

◷ Joined October 2016▧ 279 Photos and videos
hVIVO avatar
⟳ Airfinity retweeted
hVIVO@hVIVO_UK·17 Apr 2025

Interesting webinar hosted by @Airfinity on From Science to Strategy: Making RSV, hMPV, and PIV vaccines work in the real world. The session discusses the challenges of integrating combinations vaccines, the impact of seasonality on rollout strategies and the global severe burden of respiratory viruses. 👉 We are delighted that hVIVO’s presentation by Dr Andrew Catchpole on results from our hMPV pilot HCT trial at the @iRSVsociety conference in Brazil is mentioned at 1:00:40 Tune into full webinar here: youtube.com/watch?v=FLFDUVV6… #HVO #hMPV #Webinar #CHIM #Healthcare #Vaccines

Post attachment
Airfinity avatar
Airfinity@Airfinity·3 Jan 2025

Influenza positivity rose by 7% in outpatients and 5% in hospitalised patients since the week before, while RSV and hMPV increased marginally. For outpatients, influenza is the leading cause amongst all ages while hMPV is the second leading cause in children under 14.

Airfinity avatar
Airfinity@Airfinity·20 Sep 2024

The cost of #Wegovy to prevent one stroke in the US is double what’s paid by Britain’s health service, reveals new analysis by Airfinity. Read our feature in @Bloomberg to find out more. bloomberg.com/news/articles/…

World Vaccine Congress avatar
⟳ Airfinity retweeted
World Vaccine Congress@vaccinenation·30 Jul 2024

Estimates from @Airfinity suggest that the #us RSV vaccine market will drop by 2030 due to @CDCgov #acip recommendations on #vaccination strategies. #vaccinenation #vaccine #rsv #globalhealth #market vaccinenation.org/global-hea…

Airfinity avatar
Airfinity@Airfinity·24 Jul 2024

As featured in the @FT today, Airfinity has reduced its sales projections for vaccines against Respiratory Syncytial Virus (#RSV) for older adults in the US from $4.7bn per year to $1.7bn by 2030. Reach out to find out more about our estimate or the burden of RSV.

Financial Times@FT24 Jul 2024

GSK, Pfizer and Moderna face RSV vaccine sales slump on.ft.com/4frIn7k

Airfinity avatar
Airfinity@Airfinity·25 Jun 2024

Has the pandemic fundamentally changed us or the pathogens which surround us? Our study, featured in @Telegraph, shows over 40 countries or territories have reported at least one infectious disease resurgence that’s 10-fold or more over their pre-pandemic baseline.

Has the pandemic made us sicker? The momentous two year event had a profound impact on health ecosystems globally – but its legacy goes beyond a possible immunity debt. Find out more below 👇 telegraph.co.uk/global-healt…

Airfinity avatar
Airfinity@Airfinity·21 Jun 2024

Is avian influenza becoming less deadly? New analysis shows that case fatality rate (CFR) has dropped to a 33% average over the last 9 years, from 62% pre-2015. A lower CFR may signal that #H5N1 is becoming more suited to human-human infection. Reach out to learn more.

Post attachment
Airfinity avatar
Airfinity@Airfinity·5 Jun 2024

New analysis by Airfinity shows there has been a 300% rise in approved new #cancer treatments in the last two decades, with the US Cancer Moonshot Goal achievable by 2048. Click below to access the full findings on global cancer #disease burden. airfinity.com/articles/300-r…

Paul Nuki avatar
⟳ Airfinity retweeted
Paul Nuki@PaulNuki·23 May 2024

Don't miss this by @Airfinity founder @rasbech Excellent read and charts on why need to go further than a Pandemic Treaty if we are to properly protect ourselves from future threats. The good news: democracies did best with Covid... telegraph.co.uk/global-healt…